6 Popular Penny Stocks on Robinhood – Are They Good Investments?
Penny stocks have become a popular thing to put a couple of bucks into and see what happens. Worst case scenario, you’re not out a lot of money. Best case scenario, you…
Helus Pharma Inc. (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions. NSAs are synthetically engineered compounds, many of them deuterated tryptamine or phenethylamine derivatives, designed to selectively activate specific serotonin receptor subtypes.
The pipeline has three programs:
- **HLP003:** An oral deuterated psilocin analog with FDA Breakthrough Therapy Designation for adjunctive treatment of major depressive disorder (MDD). It is in the Phase 3 PARADIGM program, which comprises the APPROACH, EMBRACE and EXTEND studies, run across sites in the U.S., Europe (including Poland, Greece and Ireland), the UK and Australia.
- **HLP004:** An intramuscular deuterated DMT being developed for generalized anxiety disorder (GAD). Following completed Phase 2 adjunctive data, it is moving into a roughly 144-patient Phase 2 monotherapy study.
- **HLP005:** A preclinical phenethylamine and tryptamine derivatives program.
The company also developed the EMBARK psychological support and facilitator training model. It holds a large international patent and trademark portfolio, including 59 trademarks or applications.
It relies on licensed third parties for clinical work and manufacturing:
- **Thermo Fisher Scientific:** HLP003 manufacturing.
- **A single U.S. FDA-registered supplier:** HLP003 API.
- **Worldwide Clinical Trials:** Contract research organization (CRO).
- **Osmind:** Commercial preparation.
- **Mindset Pharma:** Licensed tryptamine molecules.
It grew in part through the 2023 acquisition of Small Pharma. Because its candidates are Schedule I controlled substances, any approved product would require DEA rescheduling before U.S. marketing. The company has no product revenue and funds operations through equity, including underwritten offerings, registered direct offerings, an at-the-market program and a Canadian base shelf prospectus. Its shares trade on Nasdaq and Cboe Canada under the ticker HELP. Updated
Penny stocks have become a popular thing to put a couple of bucks into and see what happens. Worst case scenario, you’re not out a lot of money. Best case scenario, you…
Here is a look of a few of the biggest clinical trial and FDA updates in regards to psychedelics to watch for in 2022.
Here's a quick look at six publicly traded companies developing ways to use psychedelics to treat mental health issues.
Helus Pharma Inc. (formerly Cybin Inc.) is a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions.